Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 2/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3154489 | 0.98 | ALDH1A1 (0.41) | ALDH1A1HPGDKDM4ECYP1A2CYP2A6 | |
| SCHEMBL7845462 | 0.81 | KDM4E (0.34) | ALDH1A1HPGDKDM4EMEN1KMT2A | |
| SCHEMBL7837771 | 0.77 | KDM4E (0.34) | ALDH1A1HPGDKDM4E | |
| SCHEMBL7994953 | 0.74 | ALDH1A1 (0.46) | ALDH1A1HPGDKDM4ECYP1A2CYP2A6 | |
| SCHEMBL1868060 | 0.68 | ALDH1A1 (0.36) | ALDH1A1HPGDKDM4ECYP1A2MEN1 | |
| SCHEMBL8275 | 0.67 | RYR2 (0.31) | ALDH1A1HPGDKDM4E | |
| SCHEMBL3081411 | 0.67 | ALDH1A1 (0.38) | ALDH1A1HPGDKDM4ECYP1A2MEN1 | |
| SCHEMBL9211141 | 0.67 | ALDH1A1 (0.47) | ALDH1A1HPGDKDM4ECYP1A2MEN1 | |
| SCHEMBL8694283 | 0.67 | ALDH1A1 (0.43) | ALDH1A1HPGDKDM4ECYP1A2CYP2A6 | |
| SCHEMBL1119424 | 0.65 | TRPA1 (0.59) | HPGDCYP1A2CYP2A6MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | claimed |
| WO-2022171745-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-18 | — | — | WO | claimed |
| US-5686442-A | ANTIALLERGENS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-11-11 | — | — | US | claimed |
| US-4914092-A | ANTIULCER AGENTS | SYNTHELABO (FR) | 1990-04-03 | — | — | US | claimed |
| JP-1311073-A | — | — | None | — | — | JP | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| CN-114787200-A | Method for forming inclusion complex using hydrophilic beta-cyclodextrin derivatives and compositions thereof | 塔卡美国公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3962963-A1 | METHODS FOR FORMING INCLUSION COMPLEXES WITH HYDROPHILIC ß-CYCLODEXTRIN DERIVATIVES AND COMPOSITIONS THEREOF | Taka USA, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20200347153-A1 | METHODS FOR FORMING INCLUSION COMPLEXES WITH HYDROPHILIC BETA-CYCLODEXTRIN DERIVATIVES AND COMPOSITIONS THEREOF | TAKA USA, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| WO-2020223393-A1 | METHODS FOR FORMING INCLUSION COMPLEXES WITH HYDROPHILIC β-CYCLODEXTRIN DERIVATIVES AND COMPOSITIONS THEREOF | TAKA USA, INC. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20190054022-A1 | FORMULATIONS OF SITE-SPECIFIC, MICROPARTICULATE COMPOSITIONS AND THEIR USE TO IMPROVE OUTCOME AFTER ANEURSYMAL SUBARACHNOID HEMORRHAGE | EDGE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| US-10092524-B2 | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage | EDGE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| WO-1995027510-A1 | SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS | ALZA CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
| EP-0430544-A1 | Process for resolving chiral intermediates used in making calcium channel blockers | E.R. SQUIBB & SONS, INC. (US) | 1991-06-05 | — | — | EP | disclosed |
| US-4914092-A | ANTIULCER AGENTS | SYNTHELABO (FR) | 1990-04-03 | — | — | US | disclosed |
| US-4914092-A | ANTIULCER AGENTS | SYNTHELABO (FR) | 1990-04-03 | — | — | US | disclosed |
| US-4914092-A | ANTIULCER AGENTS | SYNTHELABO (FR) | 1990-04-03 | — | — | US | disclosed |
| JP-H01311073-A | BENZOTHIAZEPIN-4-ONE DERIVATIVE, PREPARATION THEREOF, AND APPLICATION TO MEDICINE | SYNTHELABO SA | 1989-12-15 | — | — | JP | disclosed |
| US-3983106-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-09-28 | — | — | US | disclosed |
| US-3948889-A | CHEMICAL INTERMEDIATES | E. R. SQUIBB & SONS, INC. (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347153-A1 | METHODS FOR FORMING INCLUSION COMPLEXES WITH HYDROPHILIC BETA-CYCLODEXTRIN DERIVATIVES AND COMPOSITIONS THEREOF | DSC1, PDCD2L, GANC | ALDH1A1 2397/4885HPGD 2468/4885KDM4E 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.